Group of vendors, healthcare organizations opposing MU delay

For a change of pace, a group of healthcare organizations is opposing any delay for Meaningful Use (MU).

The group sent a letter to House Speaker Paul Ryan (R-Wis.), Rep. Nancy Pelosi (D-Calif.), Sen. Mitch McConnell (R-Ky.) and Sen. Harry Reid (D-Nev.), saying that changing MU without additional reforms to improving interoperability between IT systems won't benefit providers. The letter is signed by vendors and healthcare organizations: Apervita, athenahealth, Health IT Now, Intel, National Alliance on Mental Illness, New Directions Technology Consulting, Oracle, United Spinal Association and Verizon.

"Delay without reform would rob taxpayers and patients of cost savings while doing absolutely nothing to make the program work well for overburdened doctors and hospitals," the letter says. Also, MU has failed to achieve its goals of supporting an interoperable IT system that improves care quality and lowers costs.

In calling for reform, the organizations recommend changing the law regarding interoperability, including establishing a common definition of interoperability, adopting industry-developed standards for APIs, testing the interoperability of products and establishing EHR marketplaces providing all relevant data about EHRs to assist in purchasing decisions.

"We have worked constructively with the administration since the [HITECH Act] was passed on ways to improve the program and to facilitate interoperability," the letter reads. "While we have made progress, it is clear to us that the administration will need legislative support to effectively facilitate interoperability."

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The company has agreed to acquire Verve Therapeutics for an upfront payment of approximately $1 billion. The total could increase significantly, however, if certain milestones are met. One of Verve's biggest gene therapies has already received the FDA's fast track designation.

American College of Cardiology Board of Governors Chair David E. Winchester, MD, MS, examines the many benefits of working with the American Medical Association House of Delegates to bring about significant change.

“Without a more concrete and stable policy on these tariffs from the current American administration, it is likely that most manufacturers will be forced to continuously change their internal forecasts and production plans," one analyst said.